Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184733 | 0.82 | ALDH1A1 (0.54) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL254781 | 0.81 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL5941081 | 0.80 | PIN1 (0.56) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL8337648 | 0.80 | ALDH1A1 (0.57) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL4847536 | 0.79 | RORC (0.50) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL15904253 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNARAB9ANPC1HTT | |
| SCHEMBL13541712 | 0.78 | L3MBTL1 (0.51) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL3496565 | 0.78 | CA12 (0.48) | ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT | |
| SCHEMBL17700288 | 0.77 | TSHR (0.54) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL20506778 | 0.77 | ALDH1A1 (0.49) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3650042-A1 | DIMETHYL FUMARATE AND VACCINATION REGIMENS | Biogen MA Inc. (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10555993-B2 | Dimethyl fumarate and vaccination regimens | BIOGEN MA INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190247485-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3220907-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3116536-A1 | DIMETHYL FUMARATE AND VACCINATION REGIMENS | Biogen MA Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2016081355-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2015138917-A1 | DIMETHYL FUMARATE AND VACCINATION REGIMENS | BIOGEN MA INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015128492-A1 | MONOMETHYL- AND DIMETHYLFUMARATE FOR NK CELL ACTIVATION | MAGHAZACHI AZZAM A (NO) | 2015-09-03 | — | — | WO | disclosed |
| EP-2811994-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | Biogen Idec MA Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013119677-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN IDEC MA INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555993-B2 | Dimethyl fumarate and vaccination regimens | FH, HLA-DRB1, SDHB | ALDH1A1 3688/4885LMNA 4083/4885POLB 633/4885 |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | ALDH1A1 3688/4885LMNA 4083/4885POLB 633/4885 |
| US-20190247485-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, SDHB, SDHA | ALDH1A1 3954/4885LMNA 2629/4885POLB 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.